| UniProt | <a href="https://www.
Progranulin is a secreted glycoprotein composed of 7.5 tandem granulin domains:
- Precursor: 593 amino acids
- Granulin domains: Each ~60 aa with 12 conserved cysteine residues forming 6 disulfide bonds
- Signal peptide: N-terminal 17 aa for secretion
- Proteolytic processing: Cleaved by proteases (MMPs, elastase, chymotrypsin) into granulins
The 3D structure reveals the characteristic cysteine-rich granulin fold.
- Promotes neuronal survival through activation of MAPK/ERK and PI3K/Akt signaling pathways
- Stimulates neurite outgrowth and dendritic branching in cortical neurons
- Supports motor neuron survival in vitro and in vivo
- Regulates neurogenesis in the adult brain
- Modulates microglial activation toward a protective phenotype
- Reduces pro-inflammatory cytokine production (IL-6, TNF-α)
- Promotes clearance of cellular debris
- Regulates complement system activity
- Critical for lysosomal enzyme activity and function
- Binds to prosaposin and helps target enzymes to lysosomes
- Regulates autophagy flux
- Maintains neuronal lipid metabolism
- Localizes to synapses in excitatory neurons
- Regulates AMPA receptor trafficking
- Modulates long-term potentiation (LTP)
- Supports dendritic spine morphology
FTD with GRN mutations (FTD-GRN) is the most common genetic form:
- Genetics: ~5-10% of FTD cases carry GRN mutations
- Inheritance: Autosomal dominant with haploinsufficiency mechanism
- Age of onset: Typically 50-70 years
- Clinical phenotypes:
- Behavioral variant FTD (bvFTD)
- Primary progressive aphasia (PPA)
- Corticobasal syndrome (CBS)
- Progressive supranuclear palsy (PSP)
Neuropathology:
- FTLD-TDP type A pathology
- TDP-43 positive neuronal cytoplasmic inclusions (NCIs)
- Neuronal loss and gliosis in frontal and temporal cortex
- Hippocampal atrophy
Biomarkers:
- Reduced PGRN levels in CSF (50% of carriers)
- Elevated neurofilament light chain (NfL) in plasma
- Hypometabolism on FDG-PET in frontal/temporal regions
Biallelic GRN mutations cause:
- Lysosomal storage disorder
- Accumulation of ceroid lipopigments
- Childhood or adult onset
- Progressive visual loss, seizures, and dementia
PGRN variants modulate AD risk:
- Some polymorphisms associated with increased AD risk
- PGRN levels elevated in AD brain
- May have protective or harmful effects depending on context
- PGRN variants linked to PD risk in some populations
- Altered microglial responses in PD brain
- Interaction with leucine-rich repeat kinase 2 (LRRK2)
- AAV-mediated delivery: Preclinical studies show promising results
- Progranulin overexpression: Rescues lysosomal function in models
- Clinical trials planned for AAV-GRN
- Recombinant human progranulin (prGN)
- Intravenous and intrathecal administration
- Currently in Phase 1/2 trials
- Autophagy enhancers: Increase endogenous PGRN expression
- HDAC inhibitors: May upregulate GRN transcription
- Mitochondrial stabilizers: Support lysosomal function
- Antisense oligonucleotides targeting GRN
- Reduce production of toxic splice isoforms
- Preclinical validation ongoing
- CSF progranulin levels
- Plasma NfL for disease progression
- FDG-PET for treatment response
- Grn-/- mice develop age-dependent neurodegeneration
- Lipofuscinosis and microgliosis
- Behavioral deficits mimicking FTD
- AAV-mediated GRN overexpression
- Mutant GRN expression models
- Used for therapeutic screening
- Progranulin deficiency causes lysosomal dysfunction
- Microglial activation drives neurodegeneration
- Gene therapy reverses pathology in models
Grn-/- mice develop age-dependent neurodegeneration with:
- Lysosomal storage abnormalities
- Microglial activation
- Behavioral deficits mimicking FTD
AAV-mediated GRN overexpression studies show:
- Rescue of lysosomal function
- Reduction of neuroinflammation
- Improved cognitive function
- AAV-GRN in Phase 1/2 trials
- Adeno-associated virus delivery to CNS
- Autophagy enhancers
- HDAC inhibitors under development
- CSF progranulin levels (50% reduction in carriers)
- Plasma NfL for disease progression
[1] Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916-919. PMID:16862116
[2] Petkau TL, et al. Progranulin: pathological functions and clinical implications. Brain. 2012;135(Pt 12):3452-3468. PMID:22561475
[3]Ward ME, et al. Young microglia restore amyloid plaque-containing brain. Neuron. 2019;104(1):32-46. PMID:31784284
[4]Gao X, et al. Progranulin deficiency leads to enhanced macrophage activation and exacerbates pathology in mouse models of Alzheimer's disease. J Neuroinflammation. 2021;18(1):142. PMID:34044812
-
Petkau TL, et al. (2012). "Progranulin: pathological functions and clinical implications." Brain. PMID:22561475
-
Baker M, et al. (2006). "Mutations in progranulin cause tau-negative frontotemporal dementia." Nature. PMID:17077455
-
Ward ME, et al. (2019). "Progranulin deficiency reduces neural circuit connectivity." Neuron. PMID:31786023
The study of Progranulin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Petkau TL, et al. (2012). "Progranulin: pathological functions and clinical implications." Brain. PMID:22561475
- Baker M, et al. (2006). "Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17." Nature. PMID:17077455
- Ward ME, et al. (2019). "Progranulin deficiency reduces neural circuit connectivity." Neuron. PMID:31786023
- Ghosh P, et al. (2013). "The role of progranulin in Alzheimer's disease and frontotemporal dementia." Transl Neurosci. PMID:23678332
- Lui H, et al. (2016). "Progranulin haploinsufficiency mediates neuronal aging." Nat Neurosci. PMID:27282261
- Tang S, et al. (2021). "Progranulin deficiency leads to age-dependent deficits in neuronal connectivity." J Neurosci. PMID:33431565
- Huang M, et al. (2017). "Progranulin and TDP-43: from genetics to pathology." Acta Neuropathol. PMID:28102436
- Flannagan KS, et al. (2020). "Gene therapy for progranulin deficiency." Mol Ther. PMID:32065578
- See: GRN Gene - Gene encoding this protein
- See: frontotemporal dementia - Disease context
- See: TDP-43 Protein - Co-pathology
- See: Lysosomal Pathway - Cellular mechanism
|
|---|